The Role of Nitric Oxide in Doxorubicin-Induced Cardiotoxicity: Experimental Study

被引:32
|
作者
Bahadir, Aysenur [1 ]
Kurucu, Nilgun [2 ]
Kadioglu, Mine [3 ]
Yenilmez, Engin [4 ]
机构
[1] Karadeniz Tech Univ, Sch Med, Dept Pediat Hematol, Trabzon, Turkey
[2] Ankara Oncol Hosp, Dept Pediat Oncol, Ankara, Turkey
[3] Karadeniz Tech Univ, Sch Med, Dept Pharmacol, Trabzon, Turkey
[4] Karadeniz Tech Univ, Sch Med, Dept Histol, Trabzon, Turkey
关键词
Doxorubicin; Nitric oxide; Nitric oxide synthase inhibitors; HEART-FAILURE; RAT-HEART; SYNTHASE; CARDIOMYOPATHY; DYSFUNCTION; ADRIAMYCIN; TOXICITY; SUPEROXIDE; ERDOSTEINE; PREVENTION;
D O I
10.4274/Tjh.2013.0013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: We evaluated the myocardial damage in rats treated with doxorubicin (DOX) alone and in combination with nitric oxide synthase (NOS) inhibitors. Materials and Methods: Twenty-four male Sprague Dawley rats (12 weeks old, weighing 262 +/- 18 g) were randomly assigned into 4 groups (n=6). Group I was the control group. In Group II, rats were treated with intraperitoneal (ip) injections of 3 mg/kg DOX once a week for 5 weeks. In Group III, rats received weekly ip injections of 30 mg/kg L-NAME (nonspecific NOS inhibitor) 30 min before DOX injections for 5 weeks. In Group IV, rats received weekly ip injections of 3 mg/kg L-NIL (inducible NOS inhibitor) 30 min before DOX injections for 5 weeks. Rats were weighed 2 times a week. At the end of 6 weeks, hearts were excised and then fixed for light and electron microscopy evaluation and tissue lipid peroxidation (malondialdchyde). Blood samples were also obtained for measuring plasma lipid peroxidation. Results: Weight loss was observed in Group II, Group III, and Group IV. Weight loss was statistically significant in the DOX group. Findings of myocardial damage were significantly higher in animals treated with DOX only than in the control group. Histopathological findings of cardiotoxicity in rats treated with DOX in combination with L-NAME and L-NIL were not significantly different compared with the control group. The level of plasma malondialdehyde in the DOX group (9.3 +/- 3.4 mu mol/L) was higher than those of all other groups. Conclusion: Our results showed that DOX cardiotoxicity was significantly decreased when DOX was given with NO synthase inhibitors.
引用
收藏
页码:68 / 74
页数:7
相关论文
共 50 条
  • [21] Doxorubicin-induced experimental cardiotoxicity and effect of l- tryptophan on cardiotoxicity
    Narin, Figen
    Demir, Ferunda
    Akgun, Hulya
    Baykan, Ali
    Kocer, Derya
    Uzum, Kazim
    ERCIYES MEDICAL JOURNAL, 2005, 27 (01) : 7 - 16
  • [22] Chrysanthemum morifolium Extract Ameliorates Doxorubicin-Induced Cardiotoxicity by Decreasing Apoptosis
    Ono, Masaya
    Sunagawa, Yoichi
    Mochizuki, Saho
    Katagiri, Takahiro
    Takai, Hidemichi
    Iwashimizu, Sonoka
    Inai, Kyoko
    Funamoto, Masafumi
    Shimizu, Kana
    Shimizu, Satoshi
    Katanasaka, Yasufumi
    Komiyama, Maki
    Hawke, Philip
    Hara, Hideo
    Arakawa, Yoshiki
    Mori, Kiyoshi
    Asai, Akira
    Hasegawa, Koji
    Morimoto, Tatsuya
    CANCERS, 2022, 14 (03)
  • [23] Liraglutide Pretreatment Does Not Improve Acute Doxorubicin-Induced Cardiotoxicity in Rats
    Tonon, Carolina R.
    Monte, Marina G.
    Balin, Paola S.
    Fujimori, Anderson S. S.
    Ribeiro, Ana Paula D.
    Ferreira, Natalia F.
    Vieira, Nayane M.
    Cabral, Ronny P.
    Okoshi, Marina P.
    Okoshi, Katashi
    Zornoff, Leonardo A. M.
    Minicucci, Marcos F.
    Paiva, Sergio A. R.
    Gomes, Mariana J.
    Polegato, Bertha F.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (11)
  • [24] Protective effect of nebivolol on doxorubicin-induced cardiotoxicity in rats
    Mohamed, Enas Ahmed
    Kassem, Hussien H.
    ARCHIVES OF MEDICAL SCIENCE, 2018, 14 (06) : 1450 - 1458
  • [25] Cardioprotective Strategies for Doxorubicin-induced Cardiotoxicity: Present and Future
    Chaulin, A. M.
    Duplyakov, D., V
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2022, 18 (01) : 103 - 112
  • [26] Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-clinical Therapeutic Approaches
    Sheibani, Mohammad
    Azizi, Yaser
    Shayan, Maryam
    Nezamoleslami, Sadaf
    Eslami, Faezeh
    Farjoo, Mohammad Hadi
    Dehpour, Ahmad Reza
    CARDIOVASCULAR TOXICOLOGY, 2022, 22 (04) : 292 - 310
  • [27] Doxorubicin-induced oxidative stress injury: The protective effect of kumiss on cardiotoxicity
    Yilmaz, Seval
    Kaya, Emre
    Yonar, Harun
    Mendil, Ali Sefa
    JOURNAL OF THE HELLENIC VETERINARY MEDICAL SOCIETY, 2022, 73 (03): : 4545 - 4558
  • [28] Doxorubicin-Induced Cardiotoxicity and Cardioprotective Agents: Classic and New Players in the Game
    Arruda, Felipe dos Santos
    Tome, Fernanda Dias
    Miguel, Marina Pacheco
    de Menezes, Liliana Borges
    Alo Nagib, Patricia Resende
    Campos, Erica Carolina
    Soave, Danilo Figueiredo
    Nunes Celes, Mara Rabia
    CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (02) : 109 - 118
  • [29] Investigation of cardioprotective effect of lercanidipine on doxorubicin-induced cardiotoxicity
    Karakuyu, Nasif Fatih
    Savran, Mehtap
    Candan, Ibrahim Aydin
    Buyukbayram, Halil Ibrahim
    Erzurumlu, Yalcin
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2023, 396 (12) : 3635 - 3645
  • [30] Cardioprotective mechanisms of phytochemicals against doxorubicin-induced cardiotoxicity
    Abushouk, Abdelrahman Ibrahim
    Ismail, Ammar
    Salem, Amr Muhammad Abdo
    Afifi, Ahmed M.
    Abdel-Daim, Mohamed M.
    BIOMEDICINE & PHARMACOTHERAPY, 2017, 90 : 935 - 946